BETHESDA, Md., Aug. 2 /PRNewswire-FirstCall/ -- Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP - News) today announced the pricing of its initial public offering of 3,750,000 shares of its class A common stock at a price to the public of $11.50 per share. Of the shares being sold in the offering, 3,125,000 shares are being sold by Sucampo and 625,000 shares are being sold by a selling stockholder. In addition, a selling stockholder has granted the underwriters a 30-day option to purchase up to an additional 562,500 shares of class A common stock to cover over-allotments, if any. Sucampo’s class A common stock is trading on the Nasdaq Global Market under the symbol “SCMP.”
Cowen and Company, LLC is acting as the book-running manager for the offering and CIBC World Markets Corp. and Leerink Swann & Company are acting as co-managers.
The offering is being made only by means of a prospectus, a copy of which may be obtained from the prospectus department of Cowen and Company, LLC at ADP at 631-254-7106.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Sucampo Pharmaceuticals, Inc.
Sucampo is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones for the treatment of gastrointestinal, respiratory, vascular and central nervous system diseases and disorders. To learn more about Sucampo and its products, visit www.sucampo.com
Ronald Kaiser Scott Solomon Chief Financial Officer Vice President Sucampo Pharmaceuticals, Inc. Sharon Merrill Associates, Inc. 301-961-3400 617-542-5300 rkaiser@sucampo.com scmp@investorrelations.com
Source: Sucampo Pharmaceuticals, Inc.
